explore -WSS

explore

author：entertainment 2025-09-28 22:28:56 - browse：621

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Problems with a popular proposal to regulate AI in health care

leisure time

WSS

Bernie brings in new pharma CEOs to talk drug prices

How to fix the rural physician shortage in the U.S.

Global cancer cases to surge 77% by 2050, WHO report says

Johnson & Johnson sued for allegedly overpaying for workers' drugs

AI gets buy

Devoted Health’s losses in Medicare Advantage persist

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

How one medical school became remarkably diverse

Devoted Health’s losses in Medicare Advantage persist

Wildfire smoke exposes gaps in outdoor worker protections

Surgery pushed Ben Carson to fame

Moonlake's readout produced a cash windfall. Risks remain

Mom launches Girl Scout troop for LGBTQ youth in Texas

Walensky prepares to leave CDC — and Congress — behind

Top private equity targets in 2023: cardiology, clinical trials, lasers

Heart attack and stroke risk calculators need revising

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Wikipedia

Problems with a popular proposal to regulate AI in health care

Novo pauses ads for weight loss drug Wegovy amid demand

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Sea level rise could wash away turtle breeding grounds around the world, researchers say

AI gets buy

Biogen nominates mother of director’s child to replace him on board

leisure time

focus

hotspot

leisure time